Viking Therapeutics ( NASDAQ:VKTX – Get Rating ) had its price target raised by Truist Financial from $28.00 to $32.00 in a report issued on Wednesday, The Fly reports. They currently have a buy rating on the biotechnology company's stock. VKTX has been the subject of a number of other reports. StockNews.com assumed coverage on shares of Viking Therapeutics in a research note on Thursday, March 16th. They issued a sell rating for the company. Oppenheimer upped their target price on shares of Viking Therapeutics from $20.

https://www.dailypolitical.com/2023/04/02/viking-therapeutics-nasdaqvktx-price-target-increased-to-32-00-by-analysts-at-truist-financial.html

#dailypolitical